Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

FRANKFURT, Oct 29 (Reuters) - Novartis (NOVN.S), opens new tab raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but its shares fell ...

The Swiss pharmaceutical firm now forecasts 2024 core operating income growth of a high-teens percentage, compared with its previous target of a mid- to high-teens percentage. Novartis now ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...